Racura Oncology
- Short interest
- 0.01%
- 0.00 pp 30d
- as of 8 Oct 2026
- Reported shorts
- 19.4K
- Shares on issue
- 196.069M
Racura Oncology (RAC) Short Interest
Racura Oncology (ASX:RAC) had 0.01% of shares reported as short positions as of 8 Oct 2026, representing 19,354 shares. Racura Oncology operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Racura Oncology
Racura Oncology is a Phase 3 clinical biopharmaceutical company focused on developing cancer therapeutics. Their lead asset, RCDS1 (E,E-bisantrene), targets G4-DNA & RNA binding to inhibit MYC, a key cancer growth regulator, and is being advanced in multiple oncology indications.
Company profile →Racura Oncology (ASX:RAC) has 0.01% of its shares on issue reported as short positions as of 8 Oct 2026, or about 19,354 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. RAC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads RAC today
- Zanger BreakoutWatchScore 25rank 991 of 1931
- CAN SLIMWatchScore 10rank 1119 of 1541
- Minervini Trend TemplateNot a candidate
- Crowded-Short BreakoutNot a candidate
- Quality compoundersWatchScore 10rank 1282 of 1677
Prices to 13 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
RAC fundamentals
In the year to 30 Jun 2026, Racura Oncology (ASX:RAC) recorded revenue of A$3.4M and a net loss after tax of A$11.1M. A year earlier it recorded revenue of A$788.4K and a net loss after tax of A$4.8M. Year-on-year growth: revenue +334.3% (FY). Net margin −323.8%, return on equity −42.3% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest RAC news
All news- We're Hopeful That Racura Oncology (ASX:RAC) Will Use Its Cash Wisely - Simply Wall Street
googlenews · 14 Oct 2026
- Racura cleared for next dose level in Phase I lung cancer trial
stockhead · 14 Oct 2026
- Insurance Australia Group updates on RAC alliance and ACCC review
motleyfool · 13 Oct 2026
Company details
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss RAC
Start a research thread or post the first pulse update